Table 5.
Allergenic efficiency of HRP formulas in CMPA infants.
| Study | Patients | Type of Study | Study Duration | Intervention | Outcomes |
|---|---|---|---|---|---|
| Fiocchi et al., 2003 [77] | 18 infants CMPA confirmed by a double-blind placebo-controlled food challenge (DBPCFC) Age: 1–9 years (average 5 years) |
Clinical trial | 1 test | HRPF (Risolac®) | Skin Prick Test: CMP: positive in all children Soy: positive in all children Rice: positive for 8/18 children HRPF: positive for 2/18 children Specific IgEs: CMP: positive in all children Soy: positive in 13/18 children Rice: positive in 7/18 children HRPF: permanently negative Double-blind placebo-controlled food challenge (DBPCFC) with HRPF: negative in all cases |
| Fiocchi et al., 2006 [69] | 100 infants CMPA confirmed by DBPCFC Age: 3.2 ± 2.93 years |
Prospective study | 1 test | HRPF (Risolac®) | Skin Prick Test: Cow’s milk and/or CMP fraction: positive in 87/99 children Rice: positive in 4/90 children HRPF: positive in 4/86 children Specific IgEs > 0.35 KU/L: Cow’s milk and/or for a CMP fraction: in 92/95 children Rice: in 21/91 children HRP: in 4/91 children Rice specific IgEs: Rice: positive in 21/91 children (Pharmacia—Upjohn Diagnostic) and in 70/96 children (immunotransfer) HRPF: weakly positive in 6 children DBPCFC with HRPF was always negative. |
| Reche et al., 2010 [67] | 92 infants CMPA IgE-mediated confirmed by a positive Oral Food Challenge (OFC) Age: average 4.3 months (1.1 to 10) |
Prospective, open and randomized clinical trial | 2 years | 46 fed a HRPF (Blemil Arroz®/Modilac Expert Riz 1®) 46 fed a CMP-eHF |
HRPF: well tolerated in all children CMP-eHF: 1 child developed allergy to this -CMP-eHF Evolution of number of children remaining allergic: similar in both groups. |
| Vandenplas et al., 2014 [68] | 40 infants CMPA confirmed by OFC CMPA IgE-mediated or not Age: average 3.4 month (1 to 6) |
Prospective trial | 6 months | HRPF (Novalac Riz®) | Significant decrease of the allergy symptoms after 1 month Benefit confirmed after 3 and 6 months Clinical tolerance was assessed with the symptom-based score (SBS) [81], now published as the COMISS score [82,83] |